研究

Haratake N, Shimokawa M, Seto T, Yoshioka H, Yamamoto N, Nakagawa K, Mitsudomi T.

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Okada M

Feasibility of repeated ipsilateral anatomical pulmonary resection

Ueda D, Tsutani Y, Kamigaichi A, Kawamoto N, Tsubokawa N, Ito M, Mimae T, Miyata Y, Okada M.

Impact of the amount of preoperative erector spinae muscle in stage I non-small-cell lung cancer

Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M.

Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung.

Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, Kanemaru R, Watanabe K, Ninomiya K, Aragane N, Yanagitani N, Sakata Y, Seike M, Fujimoto D, Kasajima M, Kubo A, Kusumoto S, Oyamada Y, Fujiwara K, Mori M, Hashimoto M, Shingyoji M, Kodani M, Sakamoto J, Agatsuma T, Kashiwabara K, Inomata M, Tachihara M, Tanaka K, Hayashihara K, Koyama N, Matsui K, Minato K, Jingu D, Sakashita H, Hara S, Naito T, Okada A, Tanahashi M, Sato Y, Asano K, Takeda T, Nakazawa K, Harada T, Shibata K, Kato T, Miyaoka E, Yoshino I, Gemma A, Mitsudomi T.

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

Mitsudomi T, Tan D, Yang JC, Ahn MJ, Batra U, Cho BC, Cornelio G, Lim T, Mok T, Prabhash K, Reungwetwattana T, Ren SX, Singh N, Toyooka S, Wu YL, Yang PC, Yatabe Y.

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

Taniyama Y, Oze I, Koyanagi YN, Kawakatsu Y, Ito Y, Matsuda T, Matsuo K, Mitsudomi T, Ito H.

Changes in survival of patients with non-small cell lung cancer in Japan: An interrupted time series study

Toshiki Takemoto, Tetsuya Mitsudomi, Yasuhiro Tsutani

A case of “a left middle lobe of lung” with a left superior vena cava in a patient who underwent lung cancer surgery

Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Adachi H, Shimada Y, Takeshima Y, Ito H, Ikeda N, Okada M.

Discrepancy Between Radiological and Pathological Tumor Size in Early-Stage Non-Small Cell Lung Cancer: A Multicenter Study.

Mimae T, Miyata Y, Kumada T, Tsutani Y, Okada M.

The intersegmental pulmonary vein is not always located on the intersegmental plane of the lung: Evaluation with 3-dimensional volume-rendering image reconstruction.

津谷康大

早期肺癌に対する縮小手術の位置付け

津谷康大

早期肺癌に対する新たな縮小手術のエビデンス

Fujino T, Suda K, Sakai K, Murakami I, Shimizu S, Ohara S, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas

Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Koga T, Suda K, Mitsudomi T

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer

Hamada A, Suda K, Fujino T, Nishino M, Ohara S, Koga T, Kabasawa T, Chiba M, Shimoji M, Endoh M, Takemoto T, Soh J, Yanagawa N, Shiono S, Mitsudomi T

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC

Akira Hamada, Hiroyuki Oizumi, Hirohisa Kato, Jun Suzuki, Kenta Nakahashi, Satoshi Takamori, Ri Sho, Mitsuaki Sadahiro

Outcome of thoracoscopic anatomical sublobar resection under 3-dimensional computed tomography simulation

Suda K, Ohara S, Fujino T, Hamada A, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T

Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer

Suda K, Mitsudomi T

Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer

Duan J, Tan F, Bi N, Chen C, Chen KN, Cheng Y, Chu Q, Ge D, Hu J, Huang Y, Jiang T, Long H, Lu Y, Shi M, Wang J, Wang Q, Yang F, Yang N, Yao Y, Ying J, Zhou C, Zhou Q, Zhou Q, Bongiolatti S, Brunelli A, Fiorelli A, Gobbini E, Gridelli C, John T, Kim JJ, Lin SH, Metro G, Minervini F, Novoa NM, Owen DH, Rodriguez M, Sakanoue I, Scarci M, Suda K, Tabbò F, Tam TCC, Tsuchida M, Uchino J, Voltolini L, Wang J, Gao S

Expert consensus on perioperative treatment for non-small cell lung cancer

Li J, Tan F, Wang Y, Xue Q, Gao Y, Mu J, Mao Y, Zhao J, Wang D, Feng X, Shi S, Suda K, Cardillo G, Bertolaccini L, Infante MV, Van Schil PE, Gao S, He J

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

Lohinai Z, Dora D, Caldwell C, Rivard CJ, Suda K, Yu H, Rivalland G, Ellison K, Rozeboom L, Dziadziuszko R, Mitchell P, John T, Millan IS, Ren S, Hirsch FR.

Loss of STING expression is prognostic in non-small cell lung cancer

Soh, J., Toyooka, S., Shintani, Y., Okami, J., Ito, H., Ohtsuka, T., Mori, T., Watanabe, S. I., Asamura, H., Chida, M., Endo, S., Nakanishi, R., Kadokura, M., Suzuki, H., Miyaoka, E., Yoshino, I., Date, H. and Japanese Joint Committee of Lung Cancer, Registry

Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study

Namba, K., Suzawa, K., Shien, K., Miura, A., Takahashi, Y., Miyauchi, S., Araki, K., Nakata, K., Tomida, S., Tanaka, S., Miyoshi, K., Otani, S., Yamamoto, H., Okazaki, M., Sugimoto, S., Soh, J., Yamane, M. and Toyooka, S

One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective study

Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S,
Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M,
Yoshino I, Nakagawa K, West Japan Oncology G

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients
With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)

Suzuki K, Watanabe SI, Wakabayashi M, Saji H, Aokage K, Moriya Y, Yoshino I, Tsuboi M, Nakamura S, Nakamura K, Mitsudomi T, Asamura H, West Japan Oncology G, Japan Clinical Oncology G

A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer

Smeltzer MP, Scagliotti GV, Wakelee HA, Mitsudomi T, Roy UB, Clark RC, Arndt R, Pruett CD, Kelly KL, Ujhazy P, Johnson ML, Eralp Y, Barrios CH, Barlesi F, Hirsch FR, Bunn PA, International Association for the Study of Lung Cancer Coronavirus D, Clinical Trials Steering C

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H, West Japan Oncology G, Japan Clinical Oncology G

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, Chu Q, Mack PC, Cheng Y, Duan J, Fan Y, Han B, Hui Z, Liu A, Liu J, Lu Y, Ma Z, Shi M, Shu Y, Song Q, Song X, Song Y, Wang C, Wang X, Wang Z, Xu Y, Yao Y, Zhang L, Zhao M, Zhu B, Zhang J, Zhou C, Hirsch FR

Consensus for HER2 alterations testing in non-small-cell lung cancer

Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Janne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba, II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Johnson M, Garassino MC, Mok T, Mitsudomi T

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies

Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer

Heymach JV, Mitsudomi T, Harpole D, Aperghis M, Jones S, Mann H, Fouad TM, Reck M

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab+Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N, CheckMate I

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Basu Roy U, Baird AM, Ciupek A, Fox J, Manley E, Jr., Norris Xx K, Scagliotti GV, Wakelee HA, Mitsudomi T, Clark RC, Arndt R, Hirsch FR, Bunn PA, Smeltzer MP

Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

Tsutani Y, Okada M

Techniques of Minimally Invasive Posterior Basal (S10) Segmentectomies of the Lower Lobes

Tsutani Y, Imai K, Ito H, Miyata Y, Ikeda N, Nakayama H, Okada M

Adjuvant chemotherapy for high-risk pathological stage I non-small cell lung cancer

Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H, Okada M

The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma

Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Okada M

Feasibility of repeated ipsilateral anatomical pulmonary resection

Mimae T, Miyata Y, Kumada T, Tsutani Y, Okada M

Intersegmental pulmonary vein is not always located on the itersegmental plane of the lung -Evaluation with 3D volume-rendering image reconstruction

Fujiwara M, Mimae T, Tsutani Y, Miyata Y, Okada M

Complications and Survival After Lung Cancer Resection in Interstitial Lung Disease

Handa Y, Tsutani Y, Mimae T, Miyata Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M

A Multicenter Study of Complex Segmentectomy Versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer

Handa Y, Tsutani Y, Mimae T, Miyata Y, Ito H, Shimada Y, Nakayama H, Ikeda N, Okada M

Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer

Mimae T, Miyata Y, Tsutani Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M

Role of ground-glass opacity in pure invasive and lepidic component in pure solid lung adenocarcinoma for predicting aggressiveness

Kagimoto A, Tsutani Y, Okada M

Reply to Zhou et al

Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M

The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer

Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M

Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study

Mimae T, Miyata Y, Kumada T, Handa Y, Tsutani Y, Okada M

Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function

Kagimoto A, Tsutani Y, Mimae T, Miyata Y, Okada M

Segmentectomy versus wedge resection for radiological solid predominant and low metabolic non-small cell lung cancer

Oizumi S, Takamura K, Harada T, Tachihara M, Morikawa N, Honda R, Watanabe S, Asao T, Kunisaki M, Fukuhara T, Noro R, Kikuchi E, Tsutani Y, Tenma T, Kobayashi K, Dosaka-Akita H; North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group

Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024

Kagimoto A, Tsutani Y, Okada M

Segmentectomy for STAS positive lung adenocarcinoma

古賀教将, 光冨徹哉

肺癌とKRAS ーその分子生物学と治療戦略

須田健一 光冨徹哉

肺癌の分子標的治療の現状と展望